Nom du produit:2-(trans-4-Hydroxycyclohexyl)isoindoline-1,3-dione

IUPAC Name:2-[(1r,4r)-4-hydroxycyclohexyl]-2,3-dihydro-1H-isoindole-1,3-dione

CAS:99337-98-1
Formule moléculaire:C14H15NO3
Pureté:95%+
Numéro de catalogue:CM148256
Poids moléculaire:245.28

Unité d'emballage Stock disponible Prix($) Quantité
CM148256-1g in stock ǪǙŹ
CM148256-5g in stock ƿŗǙ
CM148256-10g in stock ƥľů

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:99337-98-1
Formule moléculaire:C14H15NO3
Point de fusion:-
Code SMILES:O=C1N([C@H]2CC[C@H](O)CC2)C(C3=C1C=CC=C3)=O
Densité:
Numéro de catalogue:CM148256
Poids moléculaire:245.28
Point d'ébullition:410°C at 760 mmHg
N° Mdl:
Stockage:Store at 2-8°C.

Category Infos

Cyclohexanes
Cyclohexane is an organic compound with a chemical formula C6H12. It is a colorless liquid with a pungent odor, insoluble in water, and soluble in most organic solvents such as ethanol, ether, benzene, and acetone. Cyclohexyl fragments are a common structure in both natural and synthetic drugs. It can be used as both core structure and part of achiral side chain.

Column Infos

Cadisegliatin
vTv Therapeutics announces FDA submission for first phase 3 study of Cadisegliatin in patients with type 1 diabetes. Cadisegliatin (TTP399) is developed as an adjunctive therapy to insulin for the treatment of type 1 diabetes, and the phase 3 trial evaluates its safety and efficacy.
Glucokinase (GK) is mainly concentrated in liver cells, and involved in the regulation of glucose metabolism. Cadisegliatin (TTP399) is a liver-selective glucosekinase activator with a mechanism of action different from that of antidiabetic drugs. It binds to the allosteric site of GK and restores innate glucose-regulating capacity of the liver, not disrupting the interaction between GK and GKRP. Cadisegliatin previously received a Breakthrough Therapy designation from the U.S. FDA.

Related Products